Edotreotide yttrium y-90 clinical trials
Also written 90Y-DOTATOC.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses edotreotide yttrium y-90 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- 90Y-DOTATOC
- 2
Studies by the year they started
5 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 4
David Bushnell (1) · Thomas Hope (1) · Sandeep Laroia (1) · Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (1) · Molecular Insight Pharmaceuticals, Inc. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses edotreotide yttrium y-90 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver MetastasesTerminatedEarly Phase 1Sandeep LaroiaNCT03724409Written as [90]Y-DOTATOCHow we know
- Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine TumorsActive, not recruitingEarly Phase 1David BushnellNCT03044977Written as 90Y-DOTA-3-Tyr-OctreotideHow we know
- Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine TumorCompletedEarly Phase 1Thomas HopeNCT03197012Written as 90Y-DOTA-TOCHow we know
- Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell LymphomasTerminatedPhase 2Istituto Scientifico Romagnolo per lo Studio e la cura dei TumoriNCT02488512Written as 90Y-DOTATOCHow we know
- Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid TumorsWithdrawnPhase 2Molecular Insight Pharmaceuticals, Inc.NCT00696930Written as 90Y-SMT487How we know
Codes
What other systems call edotreotide yttrium y-90 · ClinicalTrials.gg INT004742
- UNII (FDA) ABF7OG3FA3EDOTREOTIDE YTTRIUM Y-90Confirmed FDA, NLM, Wikidata
- Wikidata Q27273846edotreotide yttrium y-90Confirmed FDA, NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ABF7OG3FA3 | EDOTREOTIDE YTTRIUM Y-90 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27273846 | edotreotide yttrium y-90 | Confirmed FDA, NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.